NanoDx Revenue and Competitors

NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company's lead product, the NanoDxâ„¢ blood test, delivers biologically based results shown to confirm a concussion accurately in less than 90 seconds. The NanoDxâ„¢ platform utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics. In most cases, concussion or mild traumatic brain injury is diagnosed based on a range of subjective, symptom-based tests that are frequently inconclusive. The lack of a rapid, objective diagnostic tool means that a significant percentage of brain injuries go undiagnosed or are diagnosed inaccurately each year. An objective point-of-care system able to diagnose traumatic brain injury in minutes at the time of injury could have significant benefits, potentially leading to faster and more appropriate treatment. FDA has not yet reviewed this product and it has not been cleared. Currently for research use only.